The deal is mainly focused on Incyte’s investigational mutant calreticulin selective monoclonal antibody treatment for the blood disorder essential thrombocythemia and the chronic bone marrow disorder ...
I tested the first consumer-grade UltraViolet printer to see if it what it can do for makers, and I was impressed.